Big things happened this weekend.In a calculated move, a Chinese AI company released its newest large-language model (LLM), on the same day as the presidential inauguration. Though it took a week for most market participants to take notice, all are now paying attention. DeepSeek, the latest contender in the AI landscape, has made waves by developing an equally powerful algorithm at a fraction of the cost—and it’s open-source. The implications of this are quite significant, as is evident from the price actio ...

In the latest trading session, DaVita HealthCare (DVA) closed at $169.90, marking a +0.86% move from the previous day. This move outpaced the S&P 500's daily gain of 0.53%. Meanwhile, the Dow gained 0.93%, and the Nasdaq, a tech-heavy index, added 0.22%.Shares of the kidney dialysis provider have appreciated by 8.64% over the course of the past month, outperforming the Medical sector's gain of 1.49% and the S&P 500's gain of 2.69%.The investment community will be paying close attention to the earnings perfo ...

For Immediate ReleaseChicago, IL – January 17, 2025 – Today, Zacks Equity Research Equity Quest Diagnostics Inc. (DGX) , DaVita Inc. (DVA) , Option Care Health, Inc. (OPCH) and Addus HomeCare Corp. (ADUS) .Industry: Outpatient and Home HealthcareLink: https://www.zacks.com/commentary/2398152/4-stocks-to-monitor-in-a-dynamic-outpatient-home-health-industryThe Zacks Medical - Outpatient and Home Healthcare industry has been witnessing a rapid shift toward digital healthcare treatment. In the past few years, t ...

Company Performance - DaVita HealthCare (DVA) closed at $162.36, with a daily increase of +0.22%, underperforming the S&P 500 which gained 1.83% [1] - Over the past month, DVA shares increased by 9.78%, outperforming the Medical sector which declined by 3.48% and the S&P 500 which fell by 3.31% [1] Upcoming Earnings Report - DaVita HealthCare is expected to report an EPS of $2.21, reflecting an 18.18% increase from the same quarter last year [2] - Revenue is forecasted to be $3.25 billion, indicating a growth of 3.47% compared to the corresponding quarter of the previous year [2] Analyst Estimates - Recent changes in analyst estimates for DaVita HealthCare suggest a favorable outlook on the company's business health and profitability [3] - The Zacks Rank system, which incorporates these estimate changes, currently rates DaVita HealthCare as 1 (Strong Buy) [5] Valuation Metrics - DaVita HealthCare has a Forward P/E ratio of 14.41, which is below the industry average of 21.37, indicating it is trading at a discount [6] - The company's PEG ratio stands at 0.79, compared to the industry average of 1.88, suggesting a favorable valuation relative to expected earnings growth [7] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which DaVita belongs, has a Zacks Industry Rank of 156, placing it in the bottom 38% of over 250 industries [8]

DENVER, Jan. 15, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care provider, is celebrating 25 years of clinical care delivery and leadership in healthcare innovation. Since forming with a purpose "to give life" in 2000, DaVita has focused its efforts to improve clinical outcomes, enhance quality of life for patients and be a force for positive change for the healthcare system. By fostering an inclusive, mission-driven workforce and building strong community partnerships, DaVita is helping empower th ...

LOS ANGELES, Jan. 9, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care provider, has activated its emergency response plan as devastating wildfires spread across Southern California. DaVita's emergency response plan includes: Accounting for patients and teammates (employees), assessing facilities in the affected areas and identifying safe shelters. Transferring patients to centers that can safely provide dialysis treatment. Providing patients with relevant medical information—including prescription, ...

Stock Performance - DaVita HealthCare (DVA) closed at $152 69, marking a +0 77% increase from the previous day [1] - The stock outperformed the S&P 500's daily loss of 1 11% and the Nasdaq's loss of 1 89% [1] - Over the past month, DVA shares depreciated by 4 13%, outperforming the Medical sector's loss of 6 22% but lagging the S&P 500's loss of 1 7% [1] Earnings and Revenue Expectations - The company is expected to report EPS of $2 21, up 18 18% from the prior-year quarter [2] - Revenue is predicted to be $3 25 billion, indicating a 3 47% increase compared to the same quarter of the previous year [2] Analyst Estimates and Revisions - Recent changes to analyst estimates reflect short-term business trends, with positive revisions indicating optimism about the company's outlook [3] - The Zacks Rank system, which considers estimate changes, currently rates DVA as a Zacks Rank 2 (Buy) [5] Valuation Metrics - DaVita HealthCare has a Forward P/E ratio of 13 48, indicating a discount compared to its industry's Forward P/E of 20 18 [5] - The PEG ratio is currently 0 74, lower than the industry average of 1 83, suggesting a favorable valuation relative to earnings growth [6] Industry Overview - The Medical - Outpatient and Home Healthcare industry has a Zacks Industry Rank of 87, placing it in the top 35% of all industries [7] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Performance - DaVita HealthCare (DVA) closed at $151.53, down 0.84% from the previous trading session, underperforming the S&P 500's gain of 0.55% [1] - The upcoming earnings report is expected to show an EPS of $2.21, reflecting an 18.18% increase year-over-year, with quarterly revenue anticipated at $3.25 billion, up 3.47% from the previous year [2] Analyst Forecasts - Recent revisions to analyst forecasts for DaVita HealthCare are crucial, as they indicate near-term business trends and analysts' outlook on the company's health and profitability [3] - The Zacks Rank system, which incorporates estimate changes, currently ranks DaVita HealthCare as 2 (Buy) [5] Valuation Metrics - DaVita HealthCare has a Forward P/E ratio of 13.6, which is lower than the industry average of 19.29, indicating a valuation discount [6] - The company also has a PEG ratio of 0.74, significantly below the industry average PEG ratio of 2.06, suggesting favorable growth expectations relative to its price [7] Industry Context - The Medical - Outpatient and Home Healthcare industry, which includes DaVita HealthCare, holds a Zacks Industry Rank of 163, placing it in the bottom 36% of over 250 industries [8]

DaVita, Inc. (DVA) has witnessed strong momentum year to date. Its shares have risen 40.1% compared with the industry’s growth of 11.5%. The S&P 500 composite has gained 27.7% in the same period.DaVita, carrying a Zacks Rank #3 (Hold) at present, is witnessing an upward trend in its stock price, prompted by the company’s business model. The optimism, led by a decent third-quarter 2024 performance and the acquisition of dialysis centers, is expected to contribute further.DaVita is a leading provider of dialy ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of FMS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advice ...